Has Marko Tkach received payments from drug or device companies?

Yes. Drug and device makers reported $7,340 in general payments to Marko Tkach across 105 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marko Tkach did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marko Tkach come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marko Tkach

Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1386252310

Payments from drug & device makers

$7,340in general payments, 2019–2025

Across 105 payments — averaging $69.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Amgen$862
Abbott$649
Johnson & Johnson$606
Bayer$455
Novo Nordisk$418
plus $3K from 28 others

What the payments were for

Food & beverage$7,340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	13	$1,120
Amgen	9	$862
Abbott	5	$649
Johnson & Johnson(2 entities)	13	$606
Bayer	6	$455
Novo Nordisk	6	$418
Sanofi-aventis U.S. LLC	5	$322
Corcept Therapeutics	8	$257
Avanir Pharmaceuticals, Inc.	2	$245
Teva Pharmaceuticals USA, Inc.	2	$238
GSK	2	$223
E.r. Squibb & Sons, L.L.C.	2	$215
Boehringer Ingelheim	2	$212
Alkermes, Inc.	2	$193
Kyowa Kirin, Inc.	4	$160
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$134
Neurocrine Biosciences, Inc.	2	$132
Medtronic	2	$132
Radius Health, Inc.	2	$106
Sanofi	1	$104
Ultragenyx Pharmaceutical Inc.	1	$104
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$101
Kowa Pharmaceuticals America, Inc.	1	$98
Amneal Pharmaceuticals LLC	2	$41
Tandem Diabetes Care, Inc.	2	$32
Sequel Med Tech, LLC	1	$25
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$24
Novartis	1	$22
IBSA Pharma Inc.	1	$22
Takeda Pharmaceuticals U.S.A., Inc.	1	$22
Xeris Pharmaceuticals, Inc.	1	$18
Recordati_rare_diseases_inc.	1	$16
Lilly USA, LLC	1	$15
Alnylam Pharmaceuticals Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,340 in reported general payments places this provider in the 70th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts →

Other endocrinology, diabetes & metabolism in Fall River

Tamer YacoubFall River$1.4M
David NathanBoston$9M
Vanita ArodaBoston$4.2M
George KingBoston$3.7M
Karen MillerBoston$2.9M
Steven GrinspoonBoston$2.7M
Jason GagliaBoston$2.5M
Elaine YuBoston$1.3M
Osama HamdyBoston$1.1M
Steven RussellBoston$1.1M

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →